Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the ...

Stocks got a lift from rising hopes that the Federal Reserve will cut its main interest rate again at its next meeting in December.

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural moments.

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock ...